

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY

VOLUME 30, NUMBER 3

MARCH 2009

ORIGINAL ARTICLES

- 209 **Infection Control Practices in Assisted Living Facilities: A Response to Hepatitis B Virus Infection Outbreaks** • Ami S. Patel, PhD, MPH; Mary Beth White-Comstock, RN, CIC; C. Diane Woolard, PhD, MPH; Joseph F. Perz, DrPH
- 215 **Comparison of QuantiFERON-TB Gold In-Tube Test and Tuberculin Skin Test for Identification of Latent *Mycobacterium tuberculosis* Infection in Healthcare Staff and Association Between Positive Test Results and Known Risk Factors for Infection** • Paul Vinton, MBBS; Seema Mirhshahi, PhD; Paul Johnson, MBBS, PhD; Grant A. Jenkin, MBBS, PhD; Damien Jolley, MSc; Beverley-Ann Biggs MBBS, PhD
- 222 **Variability in the Hawthorne Effect With Regard to Hand Hygiene Performance in High- and Low-Performing Inpatient Care Units** • Erol Kohli, MPH; Judy Ptak, MSN; Randall Smith, MS; Eileen Taylor, BSN; Elizabeth A. Talbot, MD; Kathryn B. Kirkland, MD
- 226 **Evaluation of the Effectiveness of Common Hospital Hand Disinfectants Against Methicillin-Resistant *Staphylococcus aureus*, Glycopeptide-Intermediate *S. aureus*, and Heterogeneous Glycopeptide-Intermediate *S. aureus*** • Mandy Wootton, PhD; Timothy R. Walsh, PhD; Eleri M. Davies, MRCPATH; Robin A. Howe, MRCPATH
- 233 **Epidemiology of Healthcare-Associated Bloodstream Infection Caused by USA300 Strains of Methicillin-Resistant *Staphylococcus aureus* in 3 Affiliated Hospitals** • Timothy C. Jenkins, MD; Bruce D. McCollister, MD; Rohini Sharma, MD; Kim K. McFann, PhD; Nancy E. Madinger, MD; Michelle Barron, MD; Mary Bessesen, MD; Connie S. Price, MD; William J. Burman, MD
- 242 **Incidence of and Preoperative Risk Factors for *Staphylococcus aureus* Bacteremia and Chest Wound Infection After Cardiac Surgery** • Zeina A. Kanafani, MD, MHS; Jean Marie Arduino, ScD; Lawrence H. Muhlbaier, PhD; Keith S. Kaye, MD, MPH; Keith B. Allen, MD; Yehuda Carmeli, MD, MPH; G. Ralph Corey, MD; Sara E. Cosgrove, MD, MS; Thomas G. Fraser, MD; Anthony D. Harris, MD, MPH; Adolf W. Karchmer, MD; Ebbing Lautenbach, MD, MPH, MSCE; Mark E. Rupp, MD; Eric D. Peterson, MD, MPH; Walter L. Straus, MD, MPH; Vance G. Fowler, Jr., MD, MHS
- 249 **Impact of a Mandatory Infection Control Education Program on Nosocomial Acquisition of Methicillin-Resistant *Staphylococcus aureus*** • Todd C. Lee, MD; Christine Moore, ART; Janet M. Raboud, PhD; Matthew P. Muller, MD, PhD; Karen Green, MSc; Agnes Tong, MSc; Jastej Dhaliwal, MSc; Allison McGeer, MD; Mount Sinai Hospital Infection Control Team
- 257 **Nosocomial Outbreak of Infection With Pan-Drug-Resistant *Acinetobacter baumannii* in a Tertiary Care University Hospital** • Raquel Valencia, MD, MPH; Luis A. Arroyo, MD; Manuel Conde, MD, MPH, PhD; Josefa M. Aldana, MD, MPH; María-José Torres, PhD; Felipe Fernández-Cuenca, PhD; José Garnacho-Montero, MD, PhD; José M. Cisneros, MD, PhD; Carlos Ortíz, MD, PhD; Jerónimo Pachón, MD, PhD; Javier Aznar, MD, PhD




CONTENTS CONTINUED INSIDE

THE OFFICIAL JOURNAL OF THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA

THE UNIVERSITY OF CHICAGO PRESS

Enhanced Efficacy

NOW you hold ~~the~~ ^{more} power to fight for your patients



V-Link with **VitalShield**
Luer Activated Device Protective Coating

The first antimicrobial IV connector

Now kills at least 99.99% of 6 common pathogens known to cause catheter-related bloodstream infections (CR-BSIs)^{1*}

*These in vitro test results of typical devices have not been shown to correlate with a reduction in infections.

To learn more about the new V-Link device or any of our other products, contact your Baxter representative or the Baxter Product Information Center at 1-800-933-0303, or visit www.baxter.com.

The antimicrobial agent is not intended to be used as a treatment for existing infections.

Rx only. The antimicrobial agent is not intended to be used as a treatment for existing infections. For safe and proper use of this device, please refer to the complete instructions for use.

For safe and proper use of this device, please refer to the complete instructions for use.



Options at work.
Options at work.

MEDICATION DELIVERY
MEDICATION DELIVERY

Baxter

¹Data on file, Baxter Healthcare Corporation.

¹Data on file, Baxter Healthcare Corporation. Environment, V-Link, and VitalShield are trademarks of Baxter International Inc. Baxter Healthcare Corporation, Route 120 and Wilson Road, Round Lake, IL 60073 www.baxter.com 213399 09/08
Baxter, Committed to a Safer Healthcare Environment, V-Link, and VitalShield are trademarks of Baxter International Inc. Baxter Healthcare Corporation, Route 120 and Wilson Road, Round Lake, IL 60073 www.baxter.com 213399 09/08

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY

VOLUME 30, NUMBER 3

MARCH 2009

CONTENTS CONTINUED FROM COVER

- 264 **Complete Restriction of Fluoroquinolone Use to Control an Outbreak of *Clostridium difficile* Infection at a Community Hospital** • Alexander J. Kallen, MD, MPH; Angela Thompson, MMS; Polly Ristaino, MPH; Leigh Chapman, RN, BSN; Ainsley Nicholson, PhD; Bich-Thuy Sim, MD; Fernanda Lessa, MD, MPH; Umid Sharapov, MD, MSc; Elaine Fadden; Richard Boehler, MD; Carolyn Gould, MD, MS; Brandi Limbago, PhD; David Blythe, MD; L. Clifford McDonald, MD, MPH

CONCISE COMMUNICATIONS

- 273 **Nosocomial Infection, Length of Stay, and Time-Dependent Bias** • Jan Beyersmann, PhD; Thomas Kneib, PhD; Martin Schumacher, PhD; Petra Gastmeier, MD
- 277 **Challenges of Implementing National Guidelines for the Control and Prevention of Methicillin-Resistant *Staphylococcus aureus* Colonization or Infection in Acute Care Hospitals in the Republic of Ireland** • Fidelma Fitzpatrick, MD; Fiona Roche, PhD; Robert Cunney, MB; Hilary Humphreys, MD; Strategy for the Control of Antimicrobial Resistance in Ireland Infection Control Subcommittee
- 282 **Risk Factors Related to a Hospital-Associated Cluster of *Clostridium difficile* PCR Ribotype 027 Infections in Germany During 2007** • Bettina Weiss, MD; Niels Kleinkauf, MD; Tim Eckmanns, MD; Matthias an der Heiden, PhD; Matthias Neumann, RN; Harald Michels, MD; Andreas Jansen, MD
- 285 **Study of Cerebrospinal Fluid Shunt-Associated Infections in the First Year Following Placement, by the Canadian Nosocomial Infection Surveillance Program** • Joanne M. Langley, MD, MSc; Denise Gravel, MSc; Dorothy Moore, MD; Anne Matlow, MD; Joanne Embree, MD; Donna MacKinnon-Cameron, MMath; John Conly, MD; Canadian Nosocomial Infection Surveillance Program
- 289 **Successful Containment of a Norovirus Outbreak in an Acute Adult Psychiatric Area** • Susan J. Gilbride, RN, MSc; Bonita E. Lee, MD, MSc; Geoffrey D. Taylor, MD; Sarah E. Forgie, MD
- 292 **Preventing Healthcare Workers From Acquiring Influenza** • Tak Ching Ng, MSc; Nelson Lee, MD; Shu-Cheong David Hui, MD; Raymond Lai, MD; Margaret Ip, MD
- 296 **Reducing the Rates of Indeterminate Results of the QuantiFERON-TB Gold In-Tube Test During Routine Preemployment Screening for Latent Tuberculosis Infection Among Healthcare Personnel** • Cyndee Miranda, MD; Belinda Yen-Lieberman, PhD; Paul Terpeluk, DO; J. Walton Tomford, MD; Steven Gordon, MD

RESEARCH BRIEF

- 299 **Late Appearance of Hepatitis C Virus RNA After Needlestick Injury: Necessity for a More Intensive Follow-Up** • Norbert H. Gruener, MD; Malte Heeg, MD; Martin Obermeier, MD; Axel Ulsenheimer, MD; Bijan Raziorrouh, MD; Helmut Diepolder, MD; Reinhart Zachoval, MD; Maria-Christina Jung, MD

LETTERS TO THE EDITOR

- 301 **Evaluation of the Virucidal Activity of Chemical Disinfectants and Antiseptics: The European Point of View** • Graziella Morace, PhD; Kathryn Bellamy, PhD; Pierre Maris, PhD; Jochen Steinmann, PhD
Bijan Raziorrouh, MD; Helmut Diepolder, MD; Reinhart Zachoval, MD; Maria-Christina Jung, MD
- 302 **Reply to Morace et al.** • M. Khalid Ijaz, DVM, PhD; Joseph R. Rubino, BA, MA

LETTERS TO THE EDITOR

301 **Evaluation of the Virucidal Activity of Chemical Disinfectants and Antiseptics: The European Point of View** • Graziella Morace, PhD; Kathryn Bellamy, PhD; Pierre Maris, PhD; Jochen Steinmann, PhD

302 **Reply to Morace et al.** • M. Khalid Ijaz, DVM, PhD; Joseph R. Rubino, BA, MA

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY

VOLUME 30, NUMBER 3

MARCH 2009

CONTENTS CONTINUED FROM COVER

- 304 **Evaluation of the Efficacy of a Conventional Cleaning Regimen in Removing Methicillin-Resistant *Staphylococcus aureus* From Contaminated Surfaces in an Intensive Care Unit** • Mamoon A. Aldeyab, PhD; James C. McElnay, PhD; Salah M. Elshibly, MD, PhD; Carmel M. Hughes, PhD; David A. McDowell, PhD; M. Ann S. McMahon, PhD; Michael G. Scott, PhD; Mary P. Kearney, MB Bch BAO, FRCPath
- 306 **Is There a Relationship Between Monthly Rainfall and the Isolation of *Legionella* in Potable Water Systems in Spanish Healthcare Facilities?** • Jose-Maria Rivera, MD, PhD; Juan-Jose Granizo, MD, PhD; Lorenzo Aguilar, MD, PhD; Maria-Jose Giménez, BPharm, PhD; Jose-Maria Aguiar, MD; Jose Prieto, MD, PhD
- 308 **Doctors' Compliance With Hand Hygiene Guidelines in the Surgical Ward** • N. A. Chatzizacharias, MD; K. Chapple, PhD, FRCS
- 309 **Use of Microbiologic Findings to Manage Antimicrobials in the Intensive Care Unit** • Leonardo Pagani, MD; Michela Falciani, PharmD; Richard Aschbacher, BMS

An Official Publication of the Society for Healthcare Epidemiology of America

EDITOR

Suzanne F. Bradley, MD • Ann Arbor, MI

DEPUTY EDITOR

Carol A. Kauffman, MD • Ann Arbor, MI

SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD • Galveston, TX

Gina Pugliese, RN, MS • Chicago, IL

William Schaffner, MD • Nashville, TN

ASSOCIATE EDITORS

Ebbing Lautenbach, MD, MPH • Philadelphia, PA

Preeti N. Malani, MD, MSJ • Ann Arbor, MI

David Weber, MD, MPH • Chapel Hill, NC

STATISTICS CONSULTANT

Rodney L. Dunn, MS • Ann Arbor, MI

**SECTION EDITOR FOR GUIDELINES,
POSITION PAPERS, AND INVITED REVIEWS**

Carol Chenoweth, MD • Ann Arbor, MI

MANAGING EDITOR

Anne Marie McCormack • Chicago, IL

PAST EDITORS

Infection Control

Richard P. Wenzel, MD, 1980–1990 (vols. 1–11)

Infection Control and Hospital Epidemiology

Richard P. Wenzel, MD, 1991–1992 (vols. 12 and 13)

Michael D. Decker, MD, 1993–2001 (vols. 14–22)

Barry M. Farr, MD, 2002–2004 (vols. 23–25)

William R. Jarvis, MD, 2005–2006 (vols. 26 and 27)

EDITORIAL ADVISORY BOARD

Miriam Alter, PhD, MD • Atlanta, GA

Anucha Apisarnthanarak, MD • Pratumthani, Thailand

Lennox Archibald, MD, FRCP • Alachua, FL

Hilary Babcock, MD • St. Louis, MO

Elise M. Beltrami, MD, MPH • Decatur, GA

David Birnbaum, PhD, MPH • Sidney, BC

Christian Brun-Buisson, MD • Creteil, France

John P. Burke, MD • Salt Lake City, UT

David P. Calfee, MD, MS • New York, NY

Yehuda Carmeli, MD, MPH • Tel Aviv, Israel

Sara E. Cosgrove, MD, MS • Baltimore, MD

Donald E. Craven, MD • Burlington, MA

Burke A. Cunha, MD • Mineola, NY

Erika D'Agata, MD, MPH • Boston, MA

Patch Dellinger, MD • Seattle, WA

Daniel Diekema, MD • Iowa City, IA

Charles E. Edmiston, Jr., PhD • Milwaukee, WI

Theodore C. Eickhoff, MD • Denver, CO

Martin S. Favero, PhD • Irvine, CA

Jon P. Furuno, PhD • Baltimore, MD

Richard A. Garibaldi, MD • Farmington, CT

Petra Gastmeier, MD • Hanover, Germany

Dale N. Gerding, MD • Hines, IL

Donald A. Goldmann, MD • Boston, MA

Donna Haiduven, RN, PhD, CIC • Tampa, FL

Anthony D. Harris, MD, MPH • Baltimore, MD

David K. Henderson, MD • Bethesda, MD

Loreen A. Herwaldt, MD • Iowa City, IA

Peter N. R. Heseltine, MD • San Juan, CA

Karen Hoffmann, RN, CIC, MS • Chapel Hill, NC

Janine Jagger, MPH, PhD • Charlottesville, VA

John A. Jernigan, MD, MS • Atlanta, GA

James T. Lee, MD, PhD • St. Paul, MN

L. Clifford McDonald, MD • Atlanta, GA

Allison McGeer, MD • Toronto, ON

Leonard A. Mermel, DO, ScM • Providence, RI

Robert R. Muder, MD • Pittsburgh, PA

Carlene A. Muto, MD, MS • Pittsburgh, PA

Joseph M. Mylotte, MD, CIC • Buffalo, NY

David L. Paterson, MBBS, FRACP • Pittsburgh, PA

Jan Evans Patterson, MD • San Antonio, TX

Sindy M. Paul, MD • Yardley, PA

David A. Pegues, MD • Los Angeles, CA

Eli Perencevich, MD, MS • Baltimore, MD

Michael A. Pfaller, MD • Iowa City, IA

Didier Pittet, MD, MS • Geneva, Switzerland

Gina Pugliese, RN, MS • Chicago, IL

Isaam Raad, MD • Houston, TX

Jordi Rello, MD, PhD • Tarragona, Spain

Manfred L. Rotter, MD, DipBact • Vienna, Austria

Henning Rüden, MD • Berlin, Germany

William A. Rutala, PhD, MPH • Chapel Hill, NC

Lisa Saiman, MD, MPH • New York, NY

Sanjay Saint, MD, MPH • Ann Arbor, MI

William E. Scheckler, MD • Madison, WI

Lynne M. Schulster, PhD • Atlanta, GA

John A. Sellick, DO • Amherst, NY

Kent Sepkowitz, MD • New York, NY

Samir Shah, MD, MSCE • Philadelphia, PA

Andrew E. Simor, MD • Toronto, ON

Philip W. Smith, MD • Omaha, NE

Denis W. Spelman, MD • Prahan, Victoria, Australia

Jeffrey R. Starke, MD • Houston, TX

Janet E. Stout, PhD • Pittsburgh, PA

Clyde Thornberry, PhD • Franklin, TN

William Trick, MD • Chicago, IL

Antoni Trilla, MD, PhD • Barcelona, Spain

Robert A. Weinstein, MD • Chicago, IL

Andreas Widmer, MD, MS • Basel, Switzerland

Marcus Zervos, MD • Royal Oak, MI

Infection Control and Hospital Epidemiology (ISSN 0899-823X) is published monthly by the University of Chicago Press, 1427 E. 60th St., Chicago, IL 60637-2954 (<http://www.journals.uchicago.edu/ICHE/>). The editorial office is in Chicago, Illinois.

Editorial Office

Communications should be addressed to the Editor, *Infection Control and Hospital Epidemiology*, 1427 E. 60th St., Chicago, IL 60637-2954; (e-mail: iche@press.uchicago.edu; telephone: 773-773-2298, fax: 773-753-4247). Contributors should consult the Information for Authors, which is available at the journal's Web site.

Advertising

Please direct advertising inquiries to Journals Advertising, University of Chicago Press, 1427 E. 60th St., Chicago, IL 60637 (e-mail: cbarhany@press.uchicago.edu; telephone: 773-702-8187; fax: 773-702-0172). Publication of an advertisement in *Infection Control and Hospital Epidemiology* does not imply endorsement of its claims by the Society for Healthcare Epidemiology of America, by the Editor, or by the University of Chicago. Correspondence regarding advertising should be addressed to the advertising office in Chicago.

Permissions

Articles may be copied or otherwise reused without permission only to the extent permitted by Sections 107 and 108 of the US Copyright Law. Permission to copy articles for personal, internal, classroom, or library use may be obtained from the Copyright Clearance Center (<http://www.copyright.com>). For all other uses, such as copying for general distribution,

for advertising or promotional purposes, for creating new collective works, or for resale, please contact the Permissions Coordinator, Journals Division, University of Chicago Press, 1427 E. 60th St., Chicago, IL 60637 (e-mail: journalpermissions@press.uchicago.edu; fax: 773-834-3489). Articles in the public domain may be used without permission, but it is customary to contact the author.

Subscriptions

Subscription rates for 2009 are \$171 for individuals and \$401 for institutions. Additional rates for non-US subscribers and reduced rates for fellows, residents, and students are available at <http://www.journals.uchicago.edu/ICHE>. Subscription agent for Japan: Kinokuniya Company, Ltd. Individuals have the option to order directly from the University of Chicago Press. Single copy rates: individuals \$18; institutions \$40.

Please direct subscription inquiries, requests for back issues, and address changes to Journals Division, University of Chicago Press, P.O. Box 37005, Chicago, IL 60637 (e-mail: subscriptions@press.uchicago.edu; telephone: 773-753-3347 or toll-free in the United States and Canada 877-705-1878; fax: 773-753-0811 or toll-free 877-705-1879).

Postmaster: Send address changes to *Infection Control and Hospital Epidemiology*, University of Chicago Press, P.O. Box 37005, Chicago, IL 60637-2954.

Periodicals postage paid at Chicago, Illinois, and at an additional mailing office.

Published by the University of Chicago Press, Chicago, Illinois. © 2008 by the Society for Healthcare Epidemiology of America. All rights reserved. This publication is printed on acid-free paper.

OVERCOMING BACTERIAL RESISTANCE IN RESPIRATORY INFECTIONS

Practical Strategies for Effective Care
Complimentary CME/CE

View Today at www.Pneumonia-IQ.com

PNEUMONIA WEBCAST SERIES

- Issues Related to HAP, VAP and HCAP
- HCAP Patient Case
- VAP Patient Case

FACULTY

Lena M. Napolitano, MD, FACS, FCCP, FCCM

Andrew F. Shorr, MD, MPH

Join expert faculty and learn strategies for diagnosing and treating pneumonia, the second most common nosocomial infection in ICUs in the United States.

Med-IQ
Inspiring Medical Education

This activity is intended for infectious disease specialists, pulmonologists, critical care physicians, hospitalists, and hospital-based pharmacists.

This activity has been approved for AMA PRA Category 1 Credit™.

This activity is supported by an educational grant from Ortho-McNeil, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC.

©2009 Med-IQ. All rights reserved.



ORTHO-McNEIL JANSEN
SCIENTIFIC AFFAIRS, LLC



open up and
say anything

want better health care? start asking more questions. to your doctor. to your pharmacist. to your nurse. what are the test results? what about side effects? don't fully understand your prescriptions? don't leave confused. because the most important question is the one you should have asked. go to www.ahrq.gov/questionsaretheanswer or call 1-800-931-AHRQ (2477) for the 10 questions every patient should ask. **questions are the answer.**



Kills 99.99% or more
of infection causing pathogens

Maximus introduces

**Max
Guard™**
with antimicrobial protection

All the features of MaxPlus Clear™
plus Silver Antimicrobial Protection!

MaxPlus® and **MaxPlus Clear™** Advanced Luer Activated Devices are proven to assist in BSI reduction efforts. Hospitals across the nation have reported dramatic BSI reduction results with the inclusion of MaxPlus in their catheter maintenance bundles. Now the additional protection of Agion® Antimicrobial Technology is available for immunocompromised and at risk patients with MaxGuard.

MaxGuard™ with Antimicrobial Technology has been shown to kill greater than 99.99% of the most common pathogens associated with catheter related bloodstream infections providing extra prevention power for those patients who need it most. Turn up the power of prevention, call us to learn more.

Visit us at the SHEA Conference Booth #107

MaxPlus® and MaxGuard™ are registered trademarks of Medegen, Inc.
Agion® is a registered trademark of Agion Technologies, Inc.



930 Wanamaker Ave, Ontario, CA 91761-8151
Phone (909) 390-9080 Toll Free (800) 780-0012
Fax (909) 605-5894 www.maximusmedical.com

ML-3110 Rev A



Roche. In it for life.

From HIV to HAI, we are the only company with more than 20 years of experience in molecular diagnostics.

Our expertise in PCR assays and instruments can improve patients' healthcare.

As a pioneer with the COBAS® AmpliPrep/COBAS® TaqMan® System and assays for HCV, HBV, and HIV, Roche has made a significant contribution to infectious disease medicine. You can trust Roche as the only company with more than 20 years of knowledge and experience in molecular diagnostics.

The trusted company with multiple platform technologies to customize your needs.

Because every facility has its own unique demands and constraints, Roche can select the optimal platform, enabling you to better serve your institution and its patients.

Because every facility has its own unique demands and constraints, Roche can select the optimal platform, enabling you to better serve your institution and its patients.

Start-to-finish capabilities from research to manufacturing to sales, field service, and technical support.

You can depend on us for product support and technical proficiency. Roche provides in-house expertise with superior convenience and fast, personal customer service.

Now innovating PCR for detection of Healthcare Associated Infections (HAIs).

Make Roche your partner to reduce the prevalence of multidrug-resistant organisms and associated infections in your institution. Look to us for advanced assays to rapidly identify infectious agents so you can treat sooner. Trust Roche to bring its pioneering expertise in PCR assays and instruments to combat HAIs.

ROCHE, AMPLIPREP, TAQMAN, and COBAS are trademarks of Roche.
 © 2008 Roche Molecular Systems, Inc. All rights reserved.
 Not available in the United States.
 Roche Molecular Diagnostics
 4300 Hacienda Drive
 Pleasanton, CA 94568 USA
<http://molecular.roche.com>

ROCHE, AMPLIPREP, TAQMAN, and COBAS are trademarks of Roche.
 © 2008 Roche Molecular Systems, Inc. All rights reserved.
 Not available in the United States.
 Roche Molecular Diagnostics
 Pleasanton, CA 94568 USA
<http://molecular.roche.com>



We Innovate Healthcare